학술논문
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Document Type
Article
Author
Guo, Christina; Chénard-Poirier, Maxime; Roda, Desamparados; de Miguel, Maria; Harris, Samuel J; Candilejo, Irene Moreno; Sriskandarajah, Priya; Xu, Wen; Scaranti, Mariana; Constantinidou, Anastasia; King, Jenny; Parmar, Mona; Turner, Alison J; Carreira, Suzanne; Riisnaes, Ruth; Finneran, Laura; Hall, Emma; Ishikawa, Yuji; Nakai, Kiyohiko; Tunariu, Nina; Basu, Bristi; Kaiser, Martin; Lopez, Juanita Suzanne; Minchom, Anna; de Bono, Johann S; Banerji, Udai
Source
In The Lancet Oncology November 2020 21(11):1478-1488
Subject
Language
ISSN
1470-2045